Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma

The SMOOTHENED inhibitor vismodegib is FDA approved for advanced basal cell carcinoma (BCC), and shows promise in clinical trials for SONIC HEDGEHOG (SHH)-subgroup medulloblastoma (MB) patients. Clinical experience with BCC patients shows that continuous exposure to vismodegib is necessary to preven...

Fuld beskrivelse

Na minha lista:

Bibliografiske detaljer
Udgivet i:	Oncogene
Main Authors:	Rodriguez-Blanco, J, Pednekar, L, Penas, C, Li, B, Martin, V, Long, J, Lee, E, Weiss, WA, Rodriguez, C, Mehrdad, N, Nguyen, DM, Ayad, NG, Rai, P, Capobianco, AJ, Robbins, DJ
Format:	Artigo
Sprog:	Inglês
Udgivet:	2017
Fag:	Article
Online adgang:	https://ncbi.nlm.nih.gov/pmc/articles/PMC5680121/ https://ncbi.nlm.nih.gov/pubmed/28714964 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2017.232
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!

Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma

Lignende værker